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Diabetic retinopathy (DR) is characterized by the observation of apparent 
microvascular lesions but these lesions do not timely reflect retinal damage induced by 
diabetes mellitus (DM). Histologic and electrophysiological studies have shown that DR 
is a neurovascular disease with neuronal damage that is likely to underlie DR 
pathogenesis. Recent studies examining macular retinal ganglion cells (RGCs) in persons 
with DM (with and without DR) using optical coherence tomography (OCT) to quantify 
changes in the inner neuronal layers of the retina have produced inconsistent findings. 
This may be attributed to relatively small sample size, differences in OCT algorithms 
implemented to measure different RGC parameters and inadequate attempt to control for 
the effects of confounders. Taking these into consideration, we further evaluate the 
association of DM and DR with RGC loss using spectral-domain OCT. 
 
As ganglion cell bodies and their axons have different sizes and metabolic 
requirements, we questioned if the combined analysis of these structures represented by 
ganglion cell complex (GCC) in previous studies was appropriate. In 92 non-
glaucomatous eyes from 92 adults, we measured GCC thickness, and segregated 
thicknesses of the ganglion cell-inner plexiform layer (GC-IPL) and the retinal nerve 
fibre layer (RNFL) at the macula using spectral-domain OCT devices. We found that 
GCC thickness was strongly correlated to GC-IPL thickness (r=0.90, P <0.001), but 
moderately correlated to RNFL thickness (r=0.58, P <0.001). This showed that GCC has 
asymmetric representation of GC-IPL and RNFL, suggesting that the evaluation of RGCs 




Furthermore, we conducted an observational case-control study. Cases were type 2 
DM with and without DR, while controls were subjects without DM. We analyzed 227 
cases and 227 controls in Chinese matched by age and gender. RGCs were represented by 
separate GC-IPL and RNFL thicknesses measured from spectral-domain OCT macular 
scans. DR severity was graded on fundus photographs using the modified Airlie House 
Classification system. Among cases, 101 had none, 25 had mild and 101 had moderate or 
severe DR. We adjusted for age, gender, axial length, OCT signal strength, glycosylated 
haemoglobin and mean arterial blood pressure. Compared with controls, GC-IPL and 
RNFL were thinner in all cases [mean difference (95% confidence interval [CI]): GC-IPL 
-4.49µm (-2.92; -6.06), RNFL -0.93µm (-0.09; -1.85)], including cases with no DR 
[mean difference (95% CI), GC-IPL -4.37µm (-2.72; -6.02), RNFL -1.06µm (-0.10; -
2.02)]. Among cases, subjects with moderate or severe DR had thinner GC-IPL than 
subjects with no DR [adjusted mean difference (95% CI): -2.02µm (-0.11; -3.94)]. 
Additional adjustment for diabetes duration similarly showed a statistically significant 
association [adjusted mean difference (95% CI): GC-IPL -2.07µm (-0.08; -4.07)].  
 
As opposed to previous studies, we found that RGC loss, as reflected by GC-IPL 
thinning is present in subjects with DM and no apparent microvascular lesions, and such 
RGC loss is associated with increased DR severity. This observation raises the potential 
inclusion of spectral-domain OCT together with clinical routine examination of the 
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Diabetes mellitus (DM) is a worldwide health concern with its prevalence having 
increased by more than twofold during the past 20 years.
1
 Of adults with DM, a 
global estimate of 35% would have diabetic retinopathy (DR).
2
 DR impacts the 
vision significantly and accounts for about 20% of visual impairment in working-
aged adults.
3
 While DR has conventionally been viewed as damage to the retinal 
microvasculature, new insights into retinal physiology suggest that retinal ganglion 
cell (RGC) apoptosis is present, indicating that DR is likely to have a significant 
amount of neuronal damage underlying its pathogenesis.
4
 Recent studies have 
examined the association of DM and DR with retinal neuronal changes using RGC 
parameters of optical coherence tomography (OCT). However, these studies have 
yielded inconsistent findings and thus the association remains inconclusive.
5-11
 The 
inconsistent data across studies may be due to relatively small sample sizes, 
differences in OCT devices implemented to measure different RGC parameters, and 
inadequate attempts to control for the effect of confounders. 
 
1.2. Study Rationale 
 
Despite decades of research to improve visual outcome, DR remains the major 
contributing cause of blindness.
12
 The arisen of this finding is in-part due to the 
conventional use of characteristic microvascular retinal signs as the basis for clinical 
DR grading. There are a couple of pitfalls. Firstly, apparent microvascular DR lesions 
are relatively late signs of microcirculatory disturbance, as alterations in vessel 
calibre would have taken place before microvascular DR lesions manifest clinically.
13
 
Secondly, clinical investigation of diabetes-induced retinal damage solely based on 
3 
 
the integrity of retinal microvasculature without objective assessment of the neuronal 
retina gives an incomplete view of DR.
14
 These limitations inevitably translate into 
delayed diagnosis and intervention of DR, and thus losing the opportunity to preserve 
vision. For purposes of reducing the risk of visual loss and/or preventing visual 
impairment altogether, it is crucial to develop more sensitive methods to detect the 
earliest stages of DR. Progress in these areas requires a new outlook on diabetes-
induced retinal damage, including retinal neurons that plays a vital role in mediating 
vision. 
 
1.3. Specific Aims and Hypotheses 
 
Based on the above, the overall objective of the present study is to evaluate if 
structural RGC loss in DM and DR can be quantified at specific inner neuronal layers 
of the retina using parameters calculated by spectral-domain OCT. Based on this 
focus, the specific aims are: 
 
Aim 1: To evaluate the correlation of ganglion cell complex (GCC) thickness 
with separate measurements of ganglion cell-inner plexiform layer (GC-IPL) 
and retinal nerve fibre layer (RNFL) thicknesses obtained by spectral-domain 
OCT devices. 
 
The size of ganglion cell bodies that reside in the ganglion cell layer (GCL) is 10 
to 20 times the diameter of their axons in the RNFL.
15
 Hence, a combined analysis of 
ganglion cell bodies and axons, as represented by GCC thickness would have 




Aim 2: To examine the association of DM and DR with RGC loss using 
parameters calculated by spectral-domain OCT. 
 
 It has been shown in animal models of DM that neurons in the GCL undergo 
apoptosis as a mechanism of neuronal cell death.
16,17
 As neurons are unable to 
proliferate, apoptosis of these cells will result in cumulative loss leading to chronic 
neurodegeneration.
18
 The evaluation of whether gradual cell loss would reduce the 
overall number of cells remaining in the retina was performed in the retinae of 
streptozotocin diabetic rats.
19
 The study showed that after 7.5 months of DM there 
was a reduction of surviving RGCs by 10%, accompanied by a 22% and 14% 
reduction in the thickness of the inner plexiform layer (IPL) and inner nuclear layer 
(INL), respectively.
19
 These findings provide support that neuronal damage involving 
loss of RGCs occurs in DM, and could be translated as a reduction in thickness of the 
inner neuronal layers of the retina. Working on the underlying assumption that RGC 
loss at the cellular level is cumulative enough to be detected clinically using OCT, 
the present study hypothesize that DM and DR are associated with inner neuronal 


































2.1. Diabetic Retinopathy As A Microvascular Disease  
 
DR is a long-standing leading cause of preventable blindness amongst working-
aged adults worldwide.
20,21
 A thorough understanding of the current perspective in 
DR and impediment in achieving improved visual outcome is essential to prevent 
irreversible blindness in millions of people. 
 
2.1.1. Morbidity and adverse impact 
 
The number of people with DM globally has increased by more than twofold 
during the past 20 years with the emergence of type 2 DM in children, 
adolescents and young adults.
1
 The global prevalence of DM among adults aged 
between 20 and 79 years is predicted to grow dramatically from 382 million in 
2013 to 592 million by 2035 because of population aging, urbanization, 
sedentary lifestyle and increasing rates of obesity.
22,23
 Of the same age group with 
DM, a global estimate of 35% has some form of DR, and 10% have vision-
threatening DR (proliferative DR [PDR] and/or macular edema).
2
 These figures 
mirror that of a Singapore population-based study of Malay adults (aged 40-80 





DR has wide-ranging adverse impact. While early-stage non-proliferative DR 
(NPDR) may be asymptomatic, severe visual loss occurs in persons with severe 
NPDR and PDR.
25,26
 Data from an urban population aged between 40 and 65 
years showed that DR was responsible for approximately 20% of visual 





 Visual impairment leads to reduction in functional status as persons 
with vision-threatening DR are predisposed to difficulty in performing vision-
specific daily activities, such as reading newspaper or driving.
28
 Beyond its 
impact on vision, persons with DR have increased risks of systemic vascular 
complications, including congestive heart failure, nephropathy and stroke.
29-31
 
Finally, DR incurs substantial socioeconomic costs. For instance, the direct 
medical cost of DR in the United States among adults aged 40 years or older was 
estimated to be US$0.5 billion in 2004.
32
 As the expanding DM epidemic is set to 
increase the prevalence of DR by three-fold in 2050, the adverse impact of DR 




2.1.2. Definition and pathogenesis 
 
DM is primarily a chronic dysfunction of insulin release and/or activity 
resulting in impaired glucose uptake and metabolism.
34
 DM leads to 
complications in the form of accelerated tissue breakdown in various parts of the 
eye, particularly the retina.
35
 Retinopathy is recognized as the abnormality of the 





Physiologically, capillary walls are lined with endothelial cells, pericytes and 
smooth muscle cells for blood flow regulation and structural support.
36
 
Furthermore, adjacent endothelial cells form tight junctions to constitute the 
inner blood-retinal barrier (BRB).
37
 An intact BRB is required for the 
homeostatic regulation of the retinal microenvironment, and to partition retinal 





 The retina, in DR, experiences a series of hypoxic-ischemic 
changes that results in the breakdown of the BRB. Chronic exposure to 
hyperglycemia gives rise to a cascade of biochemical and physiological changes 
that lead to vascular damage.
39
 Biochemical mechanisms implicated in vascular 
damage are interconnected, and include increased oxidative stress, activity of 
protein kinase C isoforms and formation of advanced glycation end products.
40-42
 
As a result, capillary walls of the retinal microvasculature experience loss of 
endothelial cells, pericytes and smooth muscle cells forming acellular 
capillaries.
18
 Retinal areas supplied by acellular capillaries have poor blood flow 
and are thus hypoxic.
36
 Acellular capillaries have weakened vessel walls and are 
thus prone to vascular leakage. In response to hypoxia-ischemia, saccular 
outpouchings develop adjacent to non-perfused capillaries, which enhance 
vascular hyperpermeability and breakdown of BRB.
43
 Late in the disease process, 
the area of retinal ischemia gets extensive and tissue hypoxia upregulates the 
expression of vascular endothelial growth factor (VEGF).
44
 As an angiogenic 
growth factor, VEGF promotes vessel and fibrous tissue growth where their 




2.1.3. Clinical features 
 
Pathophysiological hypoxic-ischemic changes of the retinal microvasculature 
give rise to apparent microvascular lesions that characteristically distribute over 
the central 50 degrees of the retina in a non-uniform manner.
45
 The course of DR 
can take many years and its initial stage is marked by NPDR. In NPDR, the 
recognizable microvascular lesions include saccular vessel microaneurysms 
(MAs) and intraretinal blot haemorrhages, and followed by more severe signs of 
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vascular leakage, such as intraretinal hard exudates (HEs), more wide-spread and 
larger haemorrhages; hypoxic changes, such as cotton wool spots (CWSs), 
intraretinal microvascular abnormalities (IRMAs), and venous tortuosities and 
beading (Figure 2.1).
46
 The disease progresses to PDR where new vessels and 





While the integrity of retinal microvasculature forms an essential basis of DR 
pathogenesis, increasing evidence has shown that apparent microvascular lesions 
are relatively late signs of microvascular damage. Fluorescein angiography, an 
effective technique to evaluate capillary perfusion, has shown that substantial 
ischemia would have taken place prior to the onset of apparent microvascular 
lesions.
47
 Studies using computer-based retinal image analysis to measure 
vascular calibre have shown that diabetic individuals with widened arteriolar 
calibre were three to four times more likely to develop incident microvascular 
DR.
48,49
 In contrast, widened venular calibre was independently associated with 
the progression of microvascular DR,
50,51
 and even predicted risk of PDR.
51
 
Together, these findings show that a subclinical phase exists during the time 
period between the diagnosis of DM and clinical detection of apparent 
microvascular lesions, where significant microcirculatory disturbance is 
insidiously developing. Furthermore, changes in apparent microvascular lesions 









2.1.4. Clinical assessment and classification 
 
DR is clinically diagnosed and monitored based on the observation of 
ophthalmoscopic signs, i.e. apparent microvascular lesions.
53
 As an outcome of 
the Airlie House Symposium held in 1968, a standardized classification of 
retinopathy was developed.
54
 Notably, this classification was modified for use in 
landmark clinical trials in ophthalmology: the Diabetic Retinopathy Study (DRS) 
and the Early Treatment Diabetic Retinopathy Study (ETDRS) for the 
investigation of DR risk factors, etiologies and treatment strategy.
55
 The modified 
Airlie House classification system of DR (Table 2.1) is based on grading of 
seven-field colour retinal photographs taken following a standardized 
protocol.
20,56,57
 Retinopathy is classified into precise descriptive severity levels, 
which range from level 10 (absence of DR) to level 80 (total vitreous 
haemorrhage)
58
. This classification system has satisfactory reproducibility and 




Slit lamp indirect biomicroscopy, binocular indirect ophthalmoscopy and 
fundus photography are clinical routine fundus examination techniques. In 
actuality, these techniques mainly visualize the microvasculature of the retina 
because blood haemoglobin and lipid exudates stand out in contrast to the 
otherwise transparent neurosensory retina.
60
 This may have led to the pathology 
of the retinal microvasculature in DR being well-researched and established for 
both research and clinical use. Although routine examination techniques give 
important qualitative information of the retinal health state, they are unable to 
provide cross-sectional and quantifiable measures. More critically, routine 
examination does not give an overall view of DR when evidence has shown that 
11 
 
DR pathogenesis is undoubtedly underlined by damage to the neuronal 




2.1.5. Ocular treatment 
 
The current standard of care for DR treatment is to initiate pan retinal 
photocoagulation (PRP) when DR approaches or reaches the proliferative stage 
to delay visual loss.
62,63
 PRP is a tissue destructive procedure that uses laser to 
burn a large portion of the peripheral hypoxic retina for purposes of sealing leaky 
vessels and reducing oxygen demand. The efficacy of PRP for advanced DR 
stages has been demonstrated in the DRS and the ETDRS clinical trials. The 
DRS in 1981 showed that PRP can reduce the risk of severe visual loss (visual 
acuity worse than 5/200) in persons with PDR by 50% or more over five years 
64
. 
Subsequently, findings from the ETDRS showed that persons with severe NPDR 
or worse were most likely to benefit from timely PRP while those with less 





Although PRP is the primary treatment for PDR, the drawback of the current 
treatment paradigm is that only more advanced stages of DR are being treated 
when considerable degree of retinal damage has occurred. Furthermore, PRP 
reduces the risk of visual loss at the expense of other visual functions, and even 
then the reversal of visual loss is uncommon. Through the destruction of the 
peripheral neuronal retina, PRP causes significant visual side-effects, such as 






Advancement in medicine has seen the introduction of intraocular 
administration of pharmacological agent, anti-VEGF for the treatment of PDR. 
The agent is delivered into the vitreous via direct injection. Unlike PRP, anti-
VEGF therapy is non-destructive to the retina that acts by blocking VEGF 
signaling to inhibit vessel proliferation and disruption of BRB.
44
 Exploratory 
clinical trials of anti-VEGF therapy has since shown positive effect of visual 
acuity improvement in persons with PDR but its long-term systemic safety in 
patients with DM has not yet been established.
12,67
    
 
2.2. Diabetic Retinopathy As A Neurovascular Disease 
 
While DR has conventionally been viewed as damage to the retinal 
microvasculature, new insights into glutamate excitotoxicity, oxidative stress, and 
imbalance in the retinal production of neuroprotective factors suggest that RGC 
damage is present, indicating that DR is likely to have a significant amount of 
neuronal damage underlying its pathogenesis. 
 
2.2.1. Mechanisms of neuronal damage 
 
Several mechanisms of neuronal damage in DM and DR have been proposed. 
Firstly, the normal functioning of supporting cells or retinal glia is important for 
the maintenance of BRB, and the integration of vascular and neuronal activity in 
the retina.
36,60
 The main function of glial cells is to maintain homeostasis of the 
excitatory neurotransmitter, glutamate. It has been shown that in the early 
pathophysiology of DR, glial cells lose the ability in both the uptake of glutamate 
released by neurons and the conversion of glutamate to glutamine.
68,69
 Hence, the 
13 
 
extracellular glutamate increased to toxic levels, and this accumulation has been 
measured in the animal models of DM and vitreous of patients with PDR.
70,71
 
Glutamate over-activates ionotropic glutamate receptors and leads to 
uncontrolled influx of intracellular calcium ions causing neuronal cell death.
72
 
Furthermore, hyperglycemia activities several metabolic pathways (e.g. protein 
kinase C and formation of advanced glycation end products), which enhance the 
production of reactive oxygen species (ROS).
53,73
 This disrupts the balance 
between ROS level and antioxidant defense systems leading to oxidative damage. 
Hyperglycemia also reduces insulin receptor signaling in the retina.
74
 These 
biochemical changes coupled with the chronicity of hyperglycemia will likely 
stimulate progressive neuronal damage. Finally, the upregulation of VEGF and 
decreased in retinal production of neuroprotective factors (e.g. pigment 
epithelial-derived factor and somatostatin) in advanced DR states bearing 
prominent hypoxia-ischemia contributes to the breakdown of BRB, 
75
 and 
consequently allows entry of circulatory harmful agents into the neuronal 
retina.
60,76
 Together, these mechanisms suggest that neuronal damage beings 
early in the course of DR and interplays with concomitant microvascular 
changes. 
 
2.2.2. Susceptibility of  retinal ganglion cells to hypoxia-ischemia 
 
The retina is a metabolically active tissue. For this reason, the retina has high 
oxygen demand that is supplied by two different vascular beds.
77
 The main bulk 
of the outer retina receives indirect supply from an abundance of 
choriocapillaries, while the inner retina is sparsely vascularized by retinal 
capillary plexuses located in RNFL and GCL.
38,78
 When subjected to hypoxia-
14 
 
ischemia due to capillary occlusion in DR, the inner retina with its relatively low 





Amongst retinal neurons, RGCs are markedly affected by retinal hypoxia-
ischemia. RGCs are afferent neurons of the inner retina receiving oxygen and 
metabolic support from the same retinal microvasculature that is implicated in 
DR.
79,80
 RGCs have high energy consumption for the sustainability of membrane 
potentials because their unmyelinated axons projected across the retina have to 
utilize more energy than myelinated axons in the optic nerve.
81
 For purposes of 
sustaining membrane potentials and performing axonal axoplasmic transport, the 
inner retina mainly uses glycolysis to generate high-energy compounds 
(adenosine triphosphate). However, this metabolic pathway is not as efficient as 
oxidative phosphorylation that is used predominately in the outer retina.
82
 Hence, 





The notion of RGC vulnerability is supported by Baber et al.,
19
 who 
demonstrated decreased thickness of the inner neuronal layers of the retina in 
animal models of DM. Additionally, accelerated apoptosis of RGCs, as a 
mechanism of neuronal cell death was identified in postmortem human retinae 
from diabetic subjects with and without apparent microvascular DR lesions.
19
 
These data suggest that RGC damage occurs prior to the onset of apparent 
microvascular DR lesions in persons with DM, and progresses with worsening of 
hypoxia-ischemia. Despite evidence indicating RGC death in DR,
84-89
 histologic 
studies might potentially experience data loss during preparation and staining of 
15 
 
histological sections, such as autolytic changes caused by delays in tissue 
fixation. Furthermore, autopsy samples from donors with DM are highly 
selective, which limits the generalizability of study findings. 
 
2.2.3. Neuronal dysfunction in microvascular diabetic retinopathy 
 
RGCs integrate visual signals from photoreceptors via intermediate neurons, 
such as bipolar cells and transmit action potentials to the visual cortex.
90
 The 
activity of RGCs can be affected prior to the onset of apparent microvascular DR 
lesions in persons with DM. Previous studies among persons with DM and no 
microvascular DR, have shown deficits in contrast sensitivity and colour 
vision,
91-94
 as well as reduced focal electroretinography (ERG)-recorded electric 
responses of macular RGCs.
91-95
 Investigations in rats as early as three weeks 
after streptozotocin-induced DM showed delayed peak times and/or reduced 
amplitudes of ERG oscillatory potentials (OPs).
96-99
 These abnormal OP 
responses were similarly observed in human diabetics without apparent 
microvascular DR lesions.
100,101
 OPs are sensitive tools used to detect early 
deficit of neuronal interactions in the inner retina,
102
 and thus abnormal OP 
responses suggest degenerated synaptic activity involving bipolar cells, amacrine 
cells and RGCs.
103
 Taken together, the impaired ability of macular neurons to 
process visual signals prior to the onset of apparent microvascular DR lesions 
reinforce the concept that apparent microvascular DR lesions are relatively late 
signs of retinal damage, and such neuronal dysfunction originates from RGCs. 
 
A hypoxic-ischemic retinal microenvironment results in poor sustainability 
of RGC metabolic demand.
4,83
 Therefore, concurrent worsening of microvascular 
16 
 
DR would likely contribute to progressive RGC damage. The association 
between microvascular DR and neuronal damage has been demonstrated in 
previous studies using multifocal ERG, which is a technique that records separate 
electrical responses reflecting local neuronal activity from more than 100 isolated 
retinal patches. Among persons with DM of varying microvascular DR severity, 
these studies found abnormal electrical responses that corresponded to retinal 
patches containing apparent microvascular DR lesions, and paralleled the 
severity of microvascular DR.
104,105
 In a longitudinal study, baseline multifocal 
ERG recorded abnormal electrical responses that preceded the onset of new 
apparent microvascular DR lesions, which is suggestive of using multifocal ERG 
as a predictor of subsequent local retinopathy sites.
105
 Another study that exposed 
individuals to mild transient systemic hypoxia through the inhalation of test gas 
has also shown abnormal RGC responses in pattern ERG.
106
 Together, these 
findings suggest a close relationship between retinal hypoxia-ischemia and 
neuronal dysfunction. Furthermore, these findings draw the focus onto neuronal 
morphology as substantial structural damage in RGCs would have taken place 




2.2.4. Significance of retinal neurons clinical assessment  
 
The increasing evidence of RGC apoptosis and dysfunction in persons with 
DM opens up a new line of neuronal-based opportunity to supplement clinical 
routine examination for DR. The current standard of care for DR detection and 
determining the need for PRP therapy in vision-threatening DR is the subjective 
observation of apparent microvascular lesions using slit-lamp indirect 
biomicroscopy. However, clinical routine examination of DR based solely on the 
17 
 
observation of delayed apparent microvascular lesions neither timely detect 
diabetes-induced retinal damage nor give a complete view of DR. This has 
practical implications on patient care, in terms of delayed DR diagnosis and poor 
DR monitoring, which translate into poor visual outcome. In order to reduce the 
risk of visual loss, the inclusion of neuronal assessment into clinical routine 
practice would potentially give rise to timely detection of the earliest stages of 
DR and close monitoring of DR to vision-threatening states. Furthermore, since 
retinal microvasculature plays a supportive role to RGCs, an understanding of 
their interplay may be useful to facilitate the development of using neuronal 
parameters as a predictor of DR progression.  
 
2.2.5. Optical coherence tomography assessment of retinal ganglion cell 
damage 
 
The development of OCT by Huang et al.,
108
 in 1991 has been pivotal for the 
provision of important diagnostic information in multiple retinal diseases.
109
 OCT 
provides rapid, non-contact and high depth resolution in vivo imaging of the 
biological tissue.
110
 OCT creates cross-sectional image of the layered retina by 
measuring optical delay, known as signals, from longitudinal reflective 
boundaries within the retina using low-coherence interferometry.
109
 Since its 
introduction, OCT technology has quickly improved from the classic time-
domain to spectral-domain that uses a spectrometer with a multi-channel photo-
detector.
111
 When compared to its predecessor, spectral-domain OCT has an 
increased speed of measurement by more than 50 times, and thus minimizes 
motion artifacts.
111
 The speed advantage of spectral-domain OCT enables the 
acquisition of cross-sectional images with many more optical A-scans that give 
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rise to accurate three-dimensional mapping of the retinal tissue optical 
properties.
112
 Furthermore, the ultrahigh depth resolution of the spectral-domain 
system enables better delineation of the retinal layers that improves the 
assessment of retinal morphological features highly resembling a histologic 
examination.
113
 Equipped with sophisticated computer algorithm, the OCT 
system gives objective calculation of retinal parameters. The excellent reliability 
of OCT has been proven in both healthy eyes and eyes with maculopathy.
114-118
 
When compared to routine fundus examination techniques, OCT has the 
advantages to provide direct visualization of the neuronal retina,
119
 detect subtle 
morphological changes in the retinal microenvironment and provide quantitative 
assessment.  
 
Apoptosis of neurons in the GCL has been shown to take place in animal 
models of DM as a mechanism of neuronal cell death.
16,17
 Since neurons are 
unable to proliferate, it is plausible that apoptosis will result in cumulative 
chronic degeneration of the neuronal retina.
27
 Barber eta al.
19
 using streptozotocin 
diabetic rats, have demonstrated a reduction of surviving RGCs by 10%, 
accompanied by a 22% and 14% reduction in the thickness of the IPL and INL, 
respectively after 7.5 months. Hence, reduction in the thickness of the inner 
neuronal layers of the retina may be a proxy for RGC loss on the assumption that 
RGC loss at the cellular level is cumulative enough to be detected clinically 
using OCT. 
 
Intracellular levels of RGCs, namely axons, ganglion cell bodies and 
dendrites are located within the RNFL, the GCL and the IPL, respectively.
120
 
Depth of these inner neuronal layers of the retina is represented by optical 
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reflectivity in OCT tomogram (Figure 2.3). The RNFL, plexiform layers and 
limiting membranes have strong light scattering capability, and are thus 
hyperreflective. The light scattering capability of nuclear layers is low, and thus 
hyporeflective.
121
 Computer algorithm segments hyperreflective layers into 
anterior and posterior boundaries for calculation of retinal thickness as the 
distance between these two boundaries.
122
 The RNFL is defined by the inner 
limiting membrane (anterior boundary) and the outer boundary of RNFL. As the 
hyporeflective GCL has weak optical signal, it is combined with the IPL, forming 
the GC-IPL, and is defined by the outer boundary of RNFL (anterior boundary) 
and the IPL.  
 
The macula is theoretically a more suitable region than other retinal areas for 
the assessment of RGCs as approximately 50% of all RGCs are contained and 
multilayered at the macula.
123,124
 Recent studies utilizing OCT have examined the 
association of DM and DR with retinal neuronal changes using macular RGC 
parameters (Table 2.2). Findings from these OCT studies could not agree with 
histologic and electrophysiological data demonstrating that RGC loss may 
precede the onset of apparent microvascular DR lesions.
19,91-95,100,101
 While a 
study using OCT found RGC loss, as reflected by RNFL thinning in diabetic 
subjects with no apparent microvascular DR lesions,
8
 a number of other OCT 
studies found significant association only with existing clinically apparent DR.
5-7
 
On a totally opposite note, a study found thicker inner neuronal layers of the 
retina in diabetic subjects with no apparent microvascular DR lesions.
11
 
Furthermore, the few studies that examined RGC loss in increased severity of DR 






These OCT studies examining RGC loss in DM and DR have several 
limitations. Firstly, the sample size of subjects with DM was relatively small and 
mainly included DR of early stages. For the evaluation of RGC loss in increased 
severity of DR, a larger sample size is required to include DR at various stages, 
ranging from subclinical through to severe stage. Furthermore, different OCT 
devices and algorithms were implemented to measure different RGC parameters. 
A few studies measured the combined thickness of the GC-IPL and the RNFL, 
known as the GCC thickness, which may not be representative of RGC loss.
9,11
 
Ganglion cell bodies and axons of RGCs may have different temporal responses 
to injurious stimuli.
125,126
 Reasons being, the size of ganglion cell bodies is 10 to 
20 times the diameter of axons,
123
 and these structures have different metabolic 
requirements.
81
 The concern of a combined measurement has been raised in 
studies that showed that the diagnostic ability of GCC thickness in glaucoma is 
overestimated due to the inclusion of the RNFL thickness in GCC thickness 
measurement.
120,127
 Finally, the confounding effect of ocular axial length on 
retinal thickness was inadequately corrected, where a number of studies have 
demonstrated that longer ocular axial length is an independent factor of 
decreasing GCC and GC-IPL thicknesses.
127-130
 Taking these factors into 
consideration, we further evaluate the association of DM and DR with RGC 









Chapter 2 Tables 
Table 2.1. The modified Airlie House classification system of diabetic retinopathy 
Level Description 
10 No diabetic retinopathy visible. No other lesions that could be mistaken for 
diabetic retinopathy. 
14 Any combination of definite HE, CWS, IRMA and/or venous loops in the 
absence of definite MA. 
15 Retinal haemorrhage present without any definite MA. 
20 MA only with no other diabetic lesions present. 
31 MA and one or more of the following: haemorrhage or MA < SP 2A, HE, 
venous loops, questionable CWS, IRMA or VB. 
41 MA and one or more of the following: CWS, IRMA < SP 8A. 
51 MA and one or more of the following: VB, haemorrhage or MA ≥ SP 2A, 
IRMA ≥ SP 8A. 
60 FP only with no other proliferative lesions. 
61 No retinopathy and laser scatter photocoagulation scars present. 
62 Level 20 (MA only) and laser scatter photocoagulation scars present. 
63 Level 31 (Early NPDR) and laser scatter photocoagulation scars present. 
64 Levels 41 or 51 (Moderate or Severe NPDR) and laser scatter 
photocoagulation scars present. 
65 PDR < high risk characteristics, as defined in the Diabetic Retinopathy Study.  
70 PDR > high risk characteristics: 
 NVD ≥ SP 10A 
 NVD < SP 10A plus VH or PRH 
 NVE ≥ 1/2 DA plus VH or PRH 
 VH/PRH ≥ 1 DA 
80 Total VH. 
CWS = cotton wool spot; DA = disc area; DD = disc diameter; FP = fibrous 
proliferation; HE = hard exudate; IRMA = intraretinal microvascular abnormality; MA 
= microaneurysm; NPDR = non-proliferative diabetic retinopathy; NVD = new vessels 
on the disc (or within 1 DD of disc margin); NVE = new vessels elsewhere (> 1 DD 
from disc); PDR = proliferative diabetic retinopathy; PRH = panretinal haemorrhage; 
SP = standard photography; VB = venous beading; VH = vitreous haemorrhage.  
All diabetic lesions retinal haemorrhage, MA, HE, CWS, IRMA, VB, NVD, NVE, FP, 






Table 2.2. Previous studies examining the association between diabetic retinopathy and macular retinal ganglion cells using optical coherence tomography 
Author (Year) and 
Reference 
Total Sample Sizea 







DM Stratified Groups 
by DR Severity 
Results  
(subjects without DM as ref. group) 
     DM without DR DM with DR 
van Dijk et al. 
(2010)5 
79 (39/40) 3D OCT-1000  
(SD) 
RNFL, GCL & IPL 
(Parafovea & perifoveab) 
None & minimal No difference in 
neuronal layer thickness 
Thinner parafoveal GCL 
& perifoveal RNFL only 
van Dijk et al. 
(2012)6 
121 (64/57) 3D OCT-1000  
(SD) 
RNFL, GCL & IPL 
(Parafovea & perifoveab) 
None & minimal No difference in 
neuronal layer thickness 
Thinner neuronal layers, 
except perifoveal GCL 
van Dijk et al. 
(2009)7 
116 (57/59) Stratus OCT  
(TD) 
RNFL & GC-IPL 
(Parafovea & perifoveab) 
None & minimal No difference in 
neuronal layer thickness 
Thinner GC-IPL only 
Vujosevic et al. 
(2013)8 
124 (74/50 ) RS-3000  
(SD) 
RNFL & GC-IPL 
(Parafovea & perifoveab) 
None & combination of 
mild and moderate 
Thinner RNFL only 
Demir et al. 
(2014)9 
123 (93/30) RTVue-100  
(SD) 
GCC (Superior & inferior 
hemifields of 7 mm ring) 
None, mild & moderate No difference in neuronal layer thickness 
Park et al. 
(2011)10 
166 (126/40) Cirrus HD-OCT 
(SD) 
RNFL (On a circle of 1.73 
mm radius from the foveac) 
None, mild, moderate & 
severe 
No difference in neuronal layer thickness 
Araszkiewicz et al. 
(2012)11 
108 (77/31) RTVue-100  
(SD) 
GCC (Superior & inferior 
hemifields of 7 mm ring) 
None & combination of 
mild and moderate 
Thicker GCC Thinner inferior GCC 
onlyd 
DM = diabetes mellitus; DR = diabetic retinopathy; GCC = ganglion cell complex; GC-IPL = ganglion cell-inner plexiform layer; GCL = ganglion cell layer; IPL = inner 
plexiform layer; OCT = optical coherence tomography; RNFL = retinal nerve fibre layer; SD = spectral-domain; TD = time-domain. 
aInclusive of subjects with and without DM. 
bMeasured from 1-3 mm rings for parafovea, and from 3-6 mm rings for perifovea. 
cApplication of Optic Disc Cube 200X200 algorithm to the macular region. 
dDM without DR as reference group. 
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Chapter 2 Figures 
Figure 2.1. Non-proliferative diabetic retinopathy. (A) Microaneurysms (black 
arrows), and blot haemorrhages (white arrows); (B) Deep set blot haemorrhages (black 





































Figure 2.2. Proliferative diabetic retinopathy. (A) New vessels elsewhere in retinal 































Figure 2.3. Optical coherence tomogram and corresponding intraretinal layer. (Left) 
Macular tomogram showing optical reflectivity of the layered retina, (Right) and 
anatomic location of retinal neurons. (Anatomic figure taken with modification from 
Schuman J. S., Puliafito C. A.,Fujimoto J. G., Duker J. S. Optical Coherence 
Tomography of Ocular Diseases, 3
rd


























Correlation of Retinal Ganglion Cell Parameters Obtained by 



















The assessment of macular GCC by spectral-domain OCT has been used as 
parameter to detect early RGC damage in progressive and potentially blinding 
ophthalmic diseases.
131-133
 More recently, the Glaucoma 3D algorithm (OCT-HS100, 
Canon Inc., Tokyo, Japan) is developed for macular GCC analysis of glaucoma by 
segmenting the inner limiting membrane and the IPL. Equipped with a measurement 
area of 10X10 mm, the Glaucoma 3D algorithm performs the assessment of GCC 
beyond the macula to include perimacular RGCs and their axonal extensions of the 
RNFL bundles. In comparison to established algorithm (RTVue-100 GCC algorithm 
Optovue Inc., Fremont, CA) that acquires only macular data,
134
 the wider region of 
GCC assessment by Glaucoma 3D algorithm may provide spatial information on 
RGC damage along the RNFL bundles.
110
 As with any new technique, high 




Nonetheless, the combined measurement of RNFL and GC-IPL thicknesses in 
GCC assessment may overestimate the diagnostic ability of GCC thickness in optic 
neuropathy.
127
 Ganglion cell bodies and axons of RGCs exhibit different 
characteristics: the size of ganglion cell bodies is 10 to 20 times the axonal diameter, 
and the population of ganglion cell bodies has lesser variation than that of the RNFL 
bundles.
120
 Hence, ganglion cell bodies and axons when exposed to injurious stimuli 




The purposes of the present study were to assess the repeatability of Glaucoma 
3D algorithm developed for OCT-HS100 to measure macular and perimacular GCC 
thickness, and to evaluate correlation of GCC thickness with separate measurements 
28 
 
of macular GC-IPL and RNFL thicknesses by Ganglion Cell Analysis algorithm 




3.2.1. Study population 
 
In this observational cross-sectional study, a total of 92 volunteers aged 18 
years or older who met the inclusion criteria were recruited at the Singapore Eye 
Research Institute. All participants underwent a standardized and comprehensive 
ophthalmic examination, including best corrected visual acuity (BCVA) 
measurement with logarithmic minimal angle resolution (logMAR) chart, slit 
lamp biomicroscopy, dilated fundus examination, Goldmann applanation 
tonometry and visual field examination. The static refraction was measured using 
an autorefractor (Canon RK 5 Auto Ref-Keratometer, Canon Inc., Ltd., 
Tochigiken, Japan). Spherical equivalent refraction was calculated as the sum of 
the spherical value and half of the cylindrical value. Normal healthy eyes were 
defined as myopia severity <6 diopters, BCVA of logMAR ≤0.3, intraocular 
pressure <22 mmHg, clear ocular media, normal functioning status in both eyes 
and no history or evidence of macular disease, previous retinal or refractive 
surgery, neurologic disease, glaucoma, or visual field defect (as defined below). 
One randomly selected eye was studied in each eligible participant. Written 
informed consent was obtained from each participant after explanation of the 
nature and possible consequences of the study. The study adhered to the tenets of 
the Declaration of Helsinki, and ethics committee approval was obtained from 
SingHealth Centralized Institutional Review Board. 
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3.2.2. Visual field examination 
 
Standardized visual field testing was performed with static automated white-
on-white threshold perimetry (Humphrey Field Analyzer II; Carl Zeiss Meditec) 
with the central 24-2, Swedish Interactive Threshold Algorithm Standard 
programme. A visual field was defined as reliable when fixation losses were 
<20%, and false-positive and false-negative rates were <33%. A field defect was 
defined as having three or more significant (P <0.05) non-edge contiguous points 
with at least one point at P <0.01 level on the same side of the horizontal 
meridian in the pattern deviation probability plot, classified as outside normal 
limits in the glaucoma hemifield test and confirmed with at least two visual field 
examinations. 
 
3.2.3. Spectral-domain optical coherence tomography imaging 
 
The two commercially available spectral-domain OCT devices used in the 
present study were the OCT-HS100 (software version 3.0) and Cirrus HD-OCT 
(software version 6.0). The OCT-HS100 has a scan speed of 70,000 axial scans 
per scan with an axial resolution of 3 µm. The Glaucoma 3D scanning protocol in 
OCT-HS100 was used to acquire GCC data over a 10X10 mm area centered on 
the fovea with a scan pattern of 128 B-scans, each consisting of 1024 A-scans 
within a scan time of 1.9 seconds. During the Glaucoma 3D scanning process, the 
measurement grid was centered on the fovea and automatically rotated to align 
with the optic disc centre on the same axis to account for the influence of 
anatomic variation in the RNFL bundles (Figure 3.1). The inner limiting 
membrane and the outer boundary of the IPL were automatically segmented by 
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the Glaucoma 3D algorithm; the segmented layer thus led to the measurement of 
GCC thickness that comprised the RNFL and the GC-IPL (Figure 3.2). The GCC 
thickness map of the Glaucoma 3D scan comprised an inner ring (bounded by 1.5 
mm and 5 mm diameter circles) for macular GCC thickness measurement and an 
outer ring (bounded by 5 mm and 10 mm diameter circles) for perimacular GCC 
thickness measurement (Figure 3.3). Each ring comprised four subfields 
(superonasal, inferonasal, inferotemporal and superotemporal) totaling eight 
subfields. The central 1.5 mm in diameter and the nasal part of the outer ring that 
encroached onto the optic disc were excluded. The computational output of 
Glaucoma 3D scan also computed GCC thickness for the overall average, and 
superior and inferior hemifields over the 10 mm diameter circle. We further 
calculated the macular average GCC thickness, i.e. average of the four inner ring 
subfields. 
 
The Cirrus HD-OCT has a scan speed of 27,000 axial scans per second and 
an axial resolution of 5 µm. A 6X6 mm area centered on the fovea was scanned 
by the Macular Cube 200X200 scanning protocol that had 200 horizontal B-
scans, each consisting of 200 A-scans within a scan time of 1.5 seconds.
136,137
 
The automated Ganglion Cell Analysis algorithm, incorporated in Cirrus HD-
OCT software version 6.0 was used to demarcate and measure thicknesses of the 
GC-IPL and the RNFL within an elliptical annulus centered on the fovea based 
on the three-dimensional data generated from the Macular Cube 200X200 
protocol. The elliptical annulus has the following dimensions: vertical inner and 
outer diameter of 1.0 mm and 4.0 mm, respectively, and horizontal inner and 
outer diameter of 1.2 mm and 4.8 mm, respectively (Figure 3.4A). The size of 
the inner ring was chosen to exclude the area where the GCL is thin and difficult 
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to detect, whereas the size and shape of the outer ring were chosen to conform 
closely to the real macular anatomy, where the GCL is thickest in normal eyes.
120
 
The thickness map of the Ganglion Cell Analysis algorithm contained three 
sectors on either side of the horizontal midline (superotemporal, superior, 
superonasal, inferonasal, inferior and inferotemproal). The outer boundaries of 
the RNFL and the IPL were segmented by the Ganglion Cell Analysis algorithm; 
the segmented layer thus led to the measurement of the GC-IPL thickness 
(Figure 3.4B). The RNFL thickness measurement was segmented at the inner 
limiting membrane and outer boundary of the RNFL. The Ganglion Cell Analysis 
algorithm also computed the average GC-IPL and RNFL thicknesses. We further 
calculated superior hemifield and inferior hemifield thicknesses for the GC-IPL 
and the RNFL, i.e. average of the three sectors on either side of the horizontal 
midline. 
 
Each study eye was dilated with tropicamide 1% and phenylephrine 
hydrochloride 2.5%. All 92 participants underwent macular scanning on both 
spectral-domain OCT devices in the same session by a single operator. The OCT-
HS100 Glaucoma 3D scan was repeated for a subset of 34 randomly selected 
participants within an interval of 30 minutes for the purpose of assessing intra-
session repeatability of GCC thickness measurement. OCT scans showing 
algorithm segmentation error, centration error, signal strength <6, or artifacts due 
to eye movements or blinking were excluded from the analysis. Scan of 






3.2.4. Statistical analysis 
 
The characteristics of participants and GCC parameters were expressed as 
mean ± standard deviation (SD). The intraclass correlation coefficient (ICC) and 
95% confidence internal (CI) were calculated to assess the repeatability between 
two repeated measurements using OCT-HS100. ICC values between 0.81 and 
1.00 indicate almost perfect agreement, values between 0.61 and 0.80 indicate 
good agreement, and values between 0.41 and 0.60 indicate moderate agreement. 




The strength and direction of linear relationship between OCT-HS100-
measured GCC thickness, and Cirrus HD-OCT-measured GC-IPL and RNFL 
thicknesses were determined using Pearson’s correlation coefficient. Absolute r 
values between 0.68 and 1 indicate strong correlation, values between 0.36 and 
0.67 indicate moderate correlation, and values ≤0.35 indicate weak correlation.140 
A value of P <0.05 was considered statistically significant. Statistical analyses 




A total of 92 participants (56 women) were included in the present study. The 
mean ± SD age was 45 ± 14 years. The mean ± SD of ocular characteristics were as 
follow: BCVA, +0.02 ± 0.04 logMAR; spherical equivalent refraction, -0.98 ± 2.07 




Table 3.1 shows the repeatability of GCC thickness obtained by OCT-HS100.  In 
the subset of 34 participants, the GCC thickness for the overall average, and superior 
and inferior hemifields showed almost perfect agreement with ICC value of 0.992 
(95% CI: 0.983–0.996) for the overall average. The high level of agreement was 
similar for all inner ring subfields, and nasal subfields of the outer ring, with ICC 
values ranging from 0.979 (95% CI: 0.958–0.989) to 0.987 (95% CI: 0.956–0.989). 
The outer inferotemporal subfield also showed almost perfect agreement with ICC 
value of 0.868 (95% CI: 0.753–0.931). The outer superotemporal subfield had the 
lowest ICC value of 0.70 (95% CI: 0.481–0.838), indicating good agreement. 
 
Table 3.2 shows the Pearson’s correlation coefficient between OCT-HS100-
measured GCC thickness, and Cirrus HD-OCT-measured GC-IPL and RNFL 
thicknesses in all of the 92 participants. The overall average GCC thickness was 
strongly correlated with macular average GC-IPL thickness (r=0.83, P <0.001). The 
corresponding hemifields of each device also showed strong correlations. The 
strongest correlation was observed between macular average GCC thickness and 
macular average GC-IPL thickness (r=0.90, P <0.001). In comparison, the overall 
average GCC thickness was moderately correlated with macular average RNFL 
thickness (r=0.46, P <0.001). Macular average GCC thickness was also moderately 




The present study examined a novel spectral-domain OCT algorithm for the 
assessment of macular and perimacular RGCs and demonstrated high repeatability of 
GCC thickness obtained by OCT-HS100. Furthermore, we showed that GCC 
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thickness was more strongly correlated to GC-IPL thickness than RNFL thickness. 
This suggests that the evaluation of RGCs using spectral-domain OCT should be 
represented separately by GC-IPL and RNFL parameters.  
 
An estimated 50% of RGCs resides within 4.5 mm diameter of the foveal centre 
with no variability in RGC population.
124
 In contrast, axons beyond the fovea that 
retinotopically arch from superior and inferior macula to enter the corresponding 
vertical poles of the optic nerve head have considerable variability.
141
 Since the 
population of ganglion cell body differs less in a normal population, an underlying 
assumption here is that an alteration in GC-IPL thickness would be more likely to be 
a pathologic change than of normal variation. As shown in the present study, GCC 
thickness was more strongly correlated to GC-IPL thickness than RNFL thickness. 
This suggests that GCC thickness, which gives a combined analysis of GC-IPL and 
RNFL, has asymmetric representation of ganglion cell bodies in the GC-IPL and 
axons in the RNFL. Therefore, evaluation of macular RGCs should be represented by 
separate measurements of GC-IPL and RNFL thicknesses. 
 
The present study showed excellent repeatability of GCC thickness at the macula 
where the anatomical RGCs are multilayered and highly concentrated.
124
 This is 
supported by Tan et al.,
134
 who demonstrated high ICC values of 0.98 and 0.99 in 
healthy and glaucomatous eyes, respectively using RTVue-100. Furthermore, we 
showed the repeatability of GCC thickness measurement, specifically at the 
perimacula was comparable to that of macular GCC thickness. This may provide a 
new perspective for RGCs evaluation at the course of the arcuate RNFL bundles, 
which has shown to be a challenge for current exanimation techniques. For instance, 
the use of ophthalmoscopic examination to detect glaucomatous diffuse thinning or 
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wedge-shaped RNFL defect is flawed with substantial interobserver variability.
141,142
 
While spectral-domain OCT algorithm assessed peripapillary RNFL has high 
repeatability,
116
 it does not give information on the extensiveness of RNFL defect. 
Furthermore, RGC loss has been shown to be associated with retinal hypoxic stress in 
DR with microvascular lesions that are distributed non-uniformly across the retina.
78
 
However, an effective technique of localizing these structural RGC damages has not 
been proven. In this regard, a large area of RGC assessment may provide spatial and 
morphologic information to evaluate the extensiveness of RNFL defect, in addition to 





In conclusion, the present study demonstrated that the OCT-HS100 Glaucoma 3D 
algorithm can assess the macular and perimacular RGC parameters with high 
repeatability. The assessment of RGC damage along the arcuate RNFL bundles may 
be possible with OCT-HS100. Additionally, the present study showed that GCC 
thickness is more strongly correlated to GC-IPL thickness than RNFL thickness. This 
suggests that the evaluation of macular RGCs should be represented by separate 











Chapter 3 Tables 
Table 3.1. Repeatability of ganglion cell complex parameters with OCT-HS100 (n=34) 
GCC Thickness  Mean ± SD (µm) ICC (95% CI) 
Overall 93.96 ± 7.28 0.992 (0.983, 0.996) 
Superior hemifield 90.13 ± 7.30 0.984 (0.969, 0.992) 
Inferior hemifield  97.82 ± 7.52 0.982 (0.964, 0.991) 
Macula   
 Inner superonasal 117.72 ± 8.22 0.981 (0.963, 0.991) 
 Inner inferonasal 116.87 ± 8.42 0.981 (0.963, 0.991) 
 Inner inferotemporal 105.57 ± 7.79 0.979 (0.958, 0.989) 
 Inner superotemporal 99.60 ± 7.34 0.980 (0.960, 0.990) 
Perimacula   
 Outer superonasal 107.40 ± 10.65 0.987 (0.956, 0.989) 
 Outer inferonasal 118.44 ± 10.59 0.984 (0.968, 0.992) 
 Outer inferotemporal 79.35 ± 7.32 0.868 (0.753, 0.931) 
 Outer superotemporal 70.54 ± 6.51 0.700 (0.481,0.838) 
CI = confidence interval; GCC = ganglion cell complex; ICC = intraclass correlation 
coefficient; SD = standard deviation. 
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Table 3.2. Pearson’s correlation coefficient (r) between GCC thickness by OCT-HS100, and GC-IPL and RNFL thicknesses by Cirrus HD-OCT 
(n=92) 
 GCC Thickness by OCT-HS100 
















Macular superior hemifield    0.78 
0.49 
 
Macular inferior hemifield     0.82 
0.40 
GCC = ganglion cell complex; GC-IPL = ganglion cell-inner plexiform layer; RNFL = retinal nerve fibre layer. 
Top r values indicate GCC correlation with GC-IPL, while bottom r values indicate GCC correlation with RNFL.  
All r values were statistically significant (P <0.001). 
a
Macular GC-IPL and RNFL thicknesses were measured over 4 mm vertical diameter and 4.8 mm horizontal diameter. 
b
Overall average, and superior and inferior hemifields GCC thicknesses were computed over 10 mm in diameter centered on the fovea. 
c
Macular average GCC thickness was measured over 5 mm in diameter. 
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Chapter 3 Figures 
Figure 3.1. Measurement grids of OCT-HS100 Glaucoma 3D algorithm. The grids 
are centered on the fovea and rotated in alignment to the centre of the optic disc. Both 
foveal centre and optic disc centre are aligned on the same axis to account for the 
















Figure 3.2. Segmentation of ganglion cell complex (GCC) in OCT-HS100 Glaucoma 
3D tomogram. GCC consisting of retinal nerve fibre layer and ganglion cell-inner 
plexiform layer is segmented between inner limiting membrane (anterior boundary) and 


















Figure 3.3. OCT-HS100 Glaucoma 3D algorithm ganglion cell complex (GCC) 
thickness map of the right eye. Macular GCC is bounded by 1.5 mm and 5 mm 
diameter circles while perimacular GCC is bounded by 5 mm and 10 mm diameter 
circles. Thicknesses are averaged for the overall measurement, superior and inferior 
hemifields over the 10 mm diameter circle, and inner (macular GCC) and outer 
(perimacular GCC) subfields. The section of the nasal outer ring that encroach the optic 








































IIN = inner inferonasal; IIT = inner inferotemproal; ISN = inner superonasal;  
IST = inner superotemporal; OIN = outer inferonasal; OIT = outer inferotemproal;  






















Figure 3.4. Cirrus HD-OCT Ganglion Cell Analysis algorithm ganglion cell-inner 
plexiform layer (GC-IPL) thickness map of the right eye. (A) Dimensions and sectors 
of the elliptical annulus. (B) Segmented GC-IPL of a horizontal B-scan (the thickness 
was calculated as the distance between purple [outer boundary of retinal nerve fibre 












































DR remains the leading cause of preventable blindness in working-aged 
people.
12,14
 DR is clinically characterized by the observation of apparent 
microvascular lesions (e.g. microaneurysms and hard exudates). However, apparent 
microvascular lesions do not timely reflect retinal microvascular damage because 
insidious vascular changes as reflected by vessel calibre alterations would have 
developed prior to the incidence and progression of DR.
48,50,52
 Furthermore, 
experimental studies have extensively shown that RGCs are damaged in DM 
suggesting that DR also has a significant neuronal component underlying its 
pathogenesis.
18,19
 However, the clinical evaluation of neuronal damage in DM and 
DR is still not well-understood. 
 
Advances in the analysis of OCT derived images with newly developed 
algorithms, have enabled objective quantification of structural RGC loss at specific 
inner layers of the retina.
120
 In comparison to routine fundus examination techniques, 
OCT gives direct visualization of the transparent neurosensory retina that is 




Recent studies examining macular RGCs in persons with DM (with and without 
DR) using OCT to quantify changes in the inner neuronal layers of the retina have 
produced inconsistent findings. Data from these OCT studies could not agree with the 
evidence of RGC damage preceding the onset of apparent microvascular DR lesions, 
as reported by studies using other in vivo techniques, and histological materials from 
postmortem human retinae and animal models with DM.
19,143-145
 This conflicting 





demonstrated that RGC loss is only significantly associated with the onset of 
apparent microvascular DR lesions. While the study by Vujosevic et al.,
8
 found RGC 
loss prior to the onset of apparent microvascular DR lesions, this finding was not 
supported by Araszkiewicz et al.,
11
 who found thicker inner layers of the retina in 
subjects with DM. Furthermore, studies by Demir et al.,
9
 and Park et al.,
10
 examining 
RGC loss with increased severity of DR have found no significant association.
9,10
 It is 
also important to note that previous OCT studies had inadequate attempt to control 
for the confounding effect of glycemic control, blood pressure, diabetes duration and 
ocular axial length. We have previously demonstrated that the analysis of macular 
RGCs by spectral-domain OCT should be represented by separate measurements of 
GC-IPL and RNFL thicknesses. In view of these factors, we further evaluate the 
association of DM and DR with RGC loss using spectral-domain OCT (Cirrus HD-
OCT; Carl Zeiss Meditec, Dublin, CA.) that can segment the GC-IPL and the RNFL 






4.2.1. Study population 
 
We used an observational matched case-control study design. The study was 
approved by the ethics committee of SingHealth Centralised Institutional Review 
Board, and conducted in accordance to the tenets of the Declaration of Helsinki. 
Written informed consent was obtained from each participant after explanation of 




Cases were Chinese patients with type 2 DM with and without DR, ages 40–
80 years, and recruited into the Diabetes Management Project in Singapore. The 
Diabetes Management Project is a cross-sectional study investigating the factors 
influencing an effective diabetes self-management in diabetic patients with and 
without DR.
147
 Patients with DM attending the Diabetic Retinopathy Service 
outpatient clinic at the Singapore National Eye Centre for ophthalmological 
examination of DR state between December 2010 and March 2013 were 
recruited. These recruited patients were free of cognitive impairment as assessed 
by the 6-item cognitive impairment test.
148
 Medical records were used to verify 
the diagnosis of DM based on glycosylated haemoglobin (HbA1c) ≥6.5%. 
Exclusion criteria were history of glaucoma or uveitis; presence of significant 
media opacity, including dense cataract or vitreous haemorrhage; retinopathy that 
was non-diabetic in nature, epiretinal membrane or diabetic macular edema as 
determined by grading of fundus photographs and/or OCT images; and previous 
retinal laser photocoagulation or retinal surgery.  
 
Eligible cases were matched to controls selected from the Singapore Chinese 
Eye Study. Controls were volunteers without DM and/or any ocular disease in 
both eyes, and matched with cases on the basis of age (±5 years) and gender in a 
1 control:1 case ratio. The Singapore Chinese Eye Study is a population-based 
cross-sectional study of eye diseases in Chinese adults residing in Singapore and 




One study eye per participant was selected for inclusion. The study eye of 
each case was selected as the worse of the 2 eyes based on the assigned 
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retinopathy severity level (as defined below), while the study eye of each control 
was randomly selected. 
 
4.2.2. Spectral-domain optical coherence tomography retinal scanning 
 
After pupil dilation using tropicamide 1% and phenylephrine hydrochloride 
2.5%, retinal scanning was performed using Cirrus HD-OCT (Carl Zeiss 
Meditec, Dublin, CA.) to obtain measurements of the GC-IPL, the RNFL and the 
outer retina. Cirrus HD-OCT is a commercially available spectral-domain OCT 
device with a scan speed of 27,000 axial scans per second and axial resolution of 
5 µm.
127
 One macular scan was acquired using the Macular Cube 512X128 scan 
protocol where a 6X6 mm area centered on the fovea was scanned with 128 
horizontal B-scans, each consisting of 512 A-scans per B-scan (total of 65,536 
sampled points) within a scan time of 2.4 seconds in each eye (Figure 4.1).
114
 
The automated Ganglion Cell Analysis algorithm, incorporated in Cirrus HD-
OCT software version 6.0 was used to demarcate and calculate thicknesses of 
intraretinal layers. The GC-IPL parameters calculated by Ganglion Cell Analysis 
algorithm have been shown to have high diagnostic ability of early glaucoma and 
excellent intervisit reproducibility.
120,142
 The measurements of the GC-IPL, the 
RNFL and the outer retina were obtained within an elliptical annulus centered on 
the fovea based on the three-dimensional data generated from the Macular Cube 
512X128 scan protocol. Of the elliptical annulus, the size of the inner ring was 
chosen to exclude the area where the ganglion cell layer is thin and difficult to 
detect, whereas the size and shape of the outer ring were chosen to conform 
closely to the real macular anatomy, where the ganglion cell layer is thickest in 
normal eyes (Figure 4.2A).
120
 The Ganglion Cell Analysis algorithm measured 
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thicknesses of the GC-IPL, the RNFL and the outer retina by average and six 
equally sized sectors (three sectors on either side of the horizontal midline). 
Thicknesses were calculated as the distance between two segmented 
hypereflective intraretinal layers: RNFL thickness, which is the distance between 
the inner limiting membrane and outer boundary of the RNFL; GC-IPL 
thickness, which is the distance between outer boundaries of the RNFL and the 
IPL; and outer retinal thickness, which is the distance between outer plexiform 
layer and the retinal pigment epithelium (Figure 4.2B).  Rescanning was 
performed if a motion artifact (indicated by blood vessel discontinuity) was 
detected. Images with motion artifact, centration error, algorithm segmentation 
error or signal strength of less than six were excluded from the analysis. 
 
4.2.3. Assessment of diabetic retinopathy severity 
 
Retinal photography was performed using a standardized protocol.
20
 Digital 
colour fundus photographs were taken using a 45-degree
 
digital retinal camera 
(Canon CR-DGi with 10D SLR body; Canon, Tokyo, Japan) after pupil dilation. 
Two retinal photographs of each eye were obtained, one centered at the optic disc 





Retinopathy was considered to be present if any characteristic lesion as 
defined by the ETDRS severity scale was present:
45
 MAs, haemorrhages, CWSs, 
IRMAs, HEs, venous beading, and new vessels. For each eye, a retinopathy 
severity level was assigned according to a scale modified from the Airlie House 
Classification system (Table 2.1), which ranges from level 10 (absence of 
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retinopathy) to level 80 (total vitreous haemorrhage).
20,58
 The worse of the 2 eyes 
of each subject with DM as identified by a higher retinopathy severity level was 
used as the study eye. Any DR was defined as level 14 and above. We 
categorized the severity level into one of the four groups as defined in the Multi-
Ethnic Study of Atherosclerosis:
20
 no DR (level 10), mild DR (levels 14 to 20), 
moderate DR (levels 31 to 41) and severe DR (levels 51 to 60 and 65 to 70).  
 
4.2.4. Baseline characteristics and potential confounders 
 
All participants underwent monocular measurements of distance visual acuity 
in logMAR, static refraction and axial length. The static refraction was measured 
using an autorefractor (Canon RK 5 Auto Ref-Keratometer, Canon Inc., Ltd., 
Tochigiken, Japan). Spherical equivalent refraction was calculated as the sum of 
the spherical value and half of the cylindrical value. Axial length was measured 
with a noncontact partial coherence laser interferometry (IOLMaster Version 
3.01; Carl Zeiss Meditect AG, Jena, Germany). 
 
Systolic and diastolic blood pressures were measured using a digital 
automatic blood pressure monitor (Dinamap Model Pro Series DP110X-RW, 
100V2; GE Medical Systems Information Technologies, Inc., Milwaukee, WI). 
Mean arterial blood pressure was calculated as one-third of systolic plus two-
thirds of diastolic blood pressure. Hypertension was defined as systolic blood 
pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or self-reported 
physician diagnosis of hypertension. Non-fasting venous blood samples were 
obtained and analyzed at the Singapore General Hospital for biochemical testing 
of serum total, high-density lipoprotein (HDL) and low-density lipoprotein 
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(LDL) cholesterol, HbA1c, and random serum glucose. Other potential 
confounders that could influence the association, including age, gender, and 




4.2.5. Statistical analysis 
 
Continuous variables were reported as mean (SD) and median (interquartile 
range) if not normally distributed, and matched pairs were compared with paired 
t-test for normally distributed data or Wilcoxon signed rank test if highly 
skewed.
151
 Categorical variables were reported as frequency (percentage) and 
matched pairs were compared with McNemar’s test. We used generalized 
estimating equation method to account for the correlated data arising from the 
relatedness of case and control.
152
 In Model 1, we adjusted for the residual 
confounding effect of age and gender. In Model 2, we adjusted additionally for 
axial length, OCT signal strength, HbA1c, and mean arterial blood pressure. A 
third model that further adjusted for diabetes duration was used for the 
comparison of retinal neuronal thickness between DR severity stages. All 
statistical tests were two-sided. A value of P <0.05 was considered statistically 
significant and 95% CI was calculated. Statistical analysis was performed using 
SPSS (version 19.0, SPSS Inc., Chicago, IL). 
 
4.3. Results  
 
Matching on the basis of age and gender yielded 227 cases and 227 controls for 
analysis. In general, subjects with DM had significantly higher random serum 
glucose level and HbA1c; lower diastolic blood pressure, and total, HDL and LDL 
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cholesterol level; poorer distance visual acuity and greater myopic spherical 
equivalent refraction than controls (Table 4.1). Subjects with DM were more likely 
to have hypertension than controls. Among subjects with DM, 101 had no, 25 mild, 
92 moderate and 9 severe DR. Due to the small number of cases in the severe 
category, these were combined with the moderate group (n=101).  
 
Table 4.2 shows the mean difference in intraretinal layer thickness between 
subjects with DM and controls. After adjustment for age, gender, axial length, OCT 
signal strength, HbA1c, and mean arterial blood pressure, all subjects with DM (with 
and without DR) had significantly thinner average GC-IPL and average RNFL, but 
not average outer retinal layer than controls. The average GC-IPL was 4.49 µm 
thinner (95% CI: 2.92 to 6.06) and the average RNFL was 0.93 µm thinner (95% CI: 
0.09 to 1.85) in all subjects with DM than controls. When stratified by DR status 
among cases (Table 4.2), subjects with DM and no DR had a thinning of the average 
GC-IPL by 4.37 µm (95% CI: 2.72 to 6.02) and thinning of the average RNFL by 
1.06 µm (95% CI: 0.10 to 2.02) when compared with controls. In subjects with any 
DR, the average GC-IPL was 4.81 µm thinner (95% CI 2.12 to 7.50) than controls. 
When evaluated with a reduced age-gender adjusted model, effect sizes of these 
associations remained similar, except for average RNFL thinning in cases with no 
DR that did not reach significance. There was no reduction in average outer retinal 
thickness in diabetic subjects with no DR or any DR when compared with controls. 
 
As shown in Table 4.3, after additional adjustment for diabetes duration, together 
with age, gender, axial length, OCT signal strength, HbA1c, and mean arterial blood 
pressure, the average GC-IPL in subjects with moderate or severe DR was 2.07 µm 
thinner (95% CI: 0.08 to 4.07) than subjects with DM and no DR. The association 
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and its effect size remained similar even when diabetes duration was removed from 
the model. The average GC-IPL was not significantly thinner between subjects with 
mild DR and subjects with DM and no DR. There was no significant reduction in 




The present study demonstrates that, in subjects with DM, RGC neurons are 
vulnerable to damage prior to the onset of apparent microvascular DR lesions when 
compared with healthy controls, and such RGC damage is likely to be progressive 
with subsequent severe forms of DR development. OCT measures indicative of GC-
IPL and RNFL thinning, but not outer retinal thinning was associated with diabetic 
subjects with no clinically apparent DR. Furthermore, subjects with moderate or 
severe DR had thinner GC-IPL than subjects with DM and no DR. 
 
The measurement of the GC-IPL and the RNFL using OCT gives a gross 
cumulative quantitative assessment of RGCs. An underlying assumption here is that 
RGC damage at the cellular level is cumulative enough to be detected clinically with 
OCT. van Dijk et al.,
5-7
 studied macular neuronal damage in persons with type 1 and 
type 2 DM using time-domain and spectral-domain OCT, and found a thinning of the 
GCL or the RNFL in subjects with existing apparent signs of microvascular damage, 
but not in subjects who had no apparent microvascular DR lesions. While Vujosevic 
et al.,
8
 found RGC loss in diabetic subjects who had no apparent microvascular DR 
lesions, RGC loss was reflected by a thinning only of the RNFL but not the GC-IPL. 
For the purpose of quantifying macular RGC loss, the GC-IPL offers a theoretical 
advantage over the RNFL. Reason being, the size of ganglion cell bodies that reside 
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in the GCL is 10 to 20 times the diameter of their axons in the RNFL,
15
 and thus 
measurement of the relatively thicker GC-IPL may be more sensitive for detecting 
pathological change than measurement of RNFL thickness. As opposed to previous 
studies, the present study had a considerably larger sample size, and found a thinning 
of both the GC-IPL and the RNFL in diabetic subjects who have not yet developed 
apparent microvascular DR lesions. These changes mirror findings of 
electroretinography studies in diabetic subjects that reported neuronal dysfunction 
before the onset of clinically apparent DR.
100,101
 Together, these data suggest that 
neuronal apoptosis, the likely mechanism of RGC loss, may precede retinal 
microvascular pathology in DM.
19,71
 Nonetheless, one cannot exclude the possibility 
that subtle as yet clinically undetected microvascular pathology could have existed 
before (concurrent with) GC-IPL and RNFL thinning. Therefore, the present study’s 
OCT findings in diabetic subjects with no apparent microvascular lesions may reflect 
the discrepancy of scale between the relatively macroscopic clinical DR grading and 
anatomic inquiry of the inner retinal microenvironment with OCT. Changes in OCT 
parameters of the inner neuronal layers of the retina that appear to precede clinically 
apparent DR could provide clinicians with a potentially valuable biomarker of the 
earliest stages of DR. 
 
Among subjects with DM, the present study demonstrated that subjects with 
moderate or severe DR had thinner GC-IPL than subjects with no DR. This suggests 
that RGC loss, as reflected by GC-IPL thinning which begins before microvascular 
lesions become apparent is likely to progress in subsequent severe forms of DR 
development. Previous studies by Demir et al.
9
 and Park et al.,
10
 using different OCT 
algorithms to measure different RGC parameters, such as GCC thickness, did not 
demonstrate a significant association of RGC loss with increased DR severity. 
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Although the GC-IPL and the RNFL were measured as a combined thickness, it is 
still reasonable to expect changes in the OCT parameter, should there be presence of 
neuronal damage, as loss of ganglion cell bodies will lead to corresponding axonal 
loss.
153
 Nonetheless, the present study implemented an OCT algorithm that 
automatically demarcated the GC-IPL and the RNFL separately, as ganglion cell 
bodies and their axons may exhibit different temporal response to injurious stimuli 
due to their asymmetric metabolic requirements.
81,125
 The present study’s OCT 
finding is supported by electroretinography study that recorded abnormal electrical 
responses, suggesting a decreased RGC function, which not only preceded the onset 
of apparent microvascular DR lesions but also paralleled the severity of subsequent 
DR.
104
 Furthermore, the retinal site of neuronal dysfunction corresponded to the 
locality of apparent microvascular DR lesions, and in a longitudinal study, even 
predicted retinal sites of subsequent DR.
104,105
 Taken together, these findings provide 
support for the hypothesis that RGC dysfunction may contribute to the breakdown of 
the retinal microvasculature, however further experimental work will be required to 
establish any casual association that is beyond the methodology of the present study. 
The association of GC-IPL thinning with increased DR severity observed by the 
present study may therefore offer an objective clinical measure of cellular response to 
therapeutic interventions.  
 
Different mechanisms that may underlie the development of neuronal damage in 
DM and DR have been proposed. Glial cells, with their processes surrounding all 
retinal vessels release local factors to modulate retinal blood flow, and are essential 
for the integration of vascular and neuronal activity in the retina.
60,154
 It has been 
shown that shortly after the onset of DM, the ability of Müller cells (the principal glia 
of the retina) in the uptake of glutamate released by neurons, and to convert 
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glutamate to glutamine was reduced.
68,69
 Hence, glutamate accumulates to excessive 
levels,
70,71
 which leads to uncontrolled influx of intracellular calcium ions causing 
neurotoxicity.
72
 In diabetic retinae of animal models, glial cells (prominently at the 
RNFL) and RGCs have shown an increased expression of VEGF.
155
 As a result, the 
excessive level of VEGF promotes breakdown of the BRB, and thus allows entry of 
circulatory harmful agents into the neuronal retina.
76
 Furthermore, the toxic effects of 
hyperglycemia, which arise from several metabolic pathways (e.g. protein kinase C 
and formation of advanced glycation end products) not only cause circulatory 
disturbance to the retinal microvasculature but also enhance the production of 
reactive oxygen species leading to oxidative damage of retinal neurons.
73
 Taken 
together, metabolic functions of both retinal glia and neurons are altered early in DR 
progression. It is plausible that altered glial function affects the integrity of both the 
neuronal and vascular elements of the retina.
119
 Consequently, this disturbs the close 
interaction between neuronal activity and retinal blood flow, and hinders the 
homeostasis required for normal retinal function.
156
 Therefore, maintaining retinal 





Several limitations of the current study need to be discussed. Firstly, we were not 
able to examine the link with severe DR specifically, as we only had small number of 
cases with severe DR. Secondly, the cross-sectional design did not give us an 
opportunity to examine the temporal link between neuronal damage and the 
appearance of microvascular lesions. Lastly, the RNFL thickness was measured at the 
macular region, where the layer is anatomically thinner than the region around the 
optic nerve head, where it is usually measured. This thinner RNFL region may have 
introduced more measurement error. Strengths of the current study include the 
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measurement of retinal parameters at the macular region using a reliable and 
reproducible spectral-domain OCT algorithm.
120
 Furthermore, with the current 
algorithm we were able to measure specific layers of the retina (e.g. the GC-IPL). 
Standardized protocols were strictly followed during retinal photography and in the 
grading of DR severity to ensure reliable characterization of DR states. Lastly, as 
opposed to previous studies, the effect of several potential confounders was 
controlled to manifest independent associations.  
 
In summary, the present study demonstrates that RGC loss quantified by OCT is 
present in diabetic subjects who had no apparent microvascular DR lesions, and such 
neuronal damage is likely to progress in subsequent moderate or severe DR 
development. These clinical data which showed evidence of RGC loss in DM and 
DR are in agreement with that of experimental studies. Further prospective studies 















Chapter 4 Tables 
Table 4.1. Comparison of baseline characteristics between cases and controls 
 All (n=454) 
 Controls with no 
DM 
(n=227) 
Cases with DM 
(n=227) 
P value 
Demographics and systemic factors    
 Age (years), mean (SD) 58.1 (6.7) 58.3 (6.9) 0.13 
 Women, n (%) 74 (32.6) 74 (32.6) 1.0 
 Diabetes duration (years), median (IQR) 0 10.0 (5.0-20.0) <0.001 
 Random serum glucose (mmol/l), median 
(IQR) 
5.5 (5.0-6.3) 9.0 (6.6-12.3) <0.001 
 HbA1c (%), median (IQR) 5.8 (5.6-6.0) 7.4 (6.7-8.5) <0.001 
 Systolic blood pressure (mmHg), mean 
(SD) 
134.1 (17.7) 136.1 (18.0) 0.26 
 Diastolic blood pressure (mmHg), mean 
(SD) 
79.3 (10.3) 77.0 (9.3) 0.01 
 Total cholesterol (mmol/l), mean (SD) 5.6 (1.0) 4.5 (1.0) <0.001 
 HDL cholesterol (mmol/l), mean (SD) 1.2 (0.4) 1.1 (0.3) <0.001 
 LDL cholesterol (mmol/l), mean (SD) 3.5 (0.9) 2.6 (0.8) <0.001 
 Hypertension, n (%) 128 (56.4) 157 (69.2) 0.008 
Ocular factors    
 Distance visual acuity (logMAR), median 
(IQR) 
0.00 (0.00-0.10) 0.12 (0.04-0.24) <0.001 
 Spherical equivalent refraction (D), 
median (IQR) 
-0.03 (-1.31-1.00) -0.25 (-2.25-0.53) 0.01 
 Axial length (mm), mean (SD) 24.0 (1.1) 23.9 (1.3) 0.31 
 OCT signal strength, median (IQR) 9.0 (9.0-10.0) 9.0 (8.0-10.0) <0.001 
DM = diabetes mellitus; HbA1c = glycosylated haemoglobin; HDL = high-density lipoprotein; 
IQR = interquartile range; LDL = low-density lipoprotein; log MAR = logarithmic minimal angle 








Table 4.2. Mean difference in µm (95% confidence interval) in intraretinal layer thickness of 
retinal ganglion cells and outer retina in subjects with diabetes compared with controls 
 Difference in average GC-IPL thickness 
 Age-gender adjusted Model 2
a
 
Controls with no DM (Reference) (Reference) 
Cases with DM (n=227) -3.74 (-4.85, -2.64) -4.49 (-6.06, -2.92) 
Cases stratified by DR status   
 No DR (n=101) -3.37 (-4.90, -1.84) -4.37 (-6.02, -2.72) 
 Any DR (n=126) -4.03 (-5.40, -2.67) -4.81 (-7.50, -2.12) 
 Difference in average RNFL thickness 
 Age-gender adjusted Model 2
a
 
Controls with no DM (Reference) (Reference) 
Cases with DM (n=227) -0.77 (-1.42, -0.12) -0.93 (-1.85, -0.09) 
Cases stratified by DR status   
 No DR (n=101) -0.75 (-1.52, 0.02) -1.06 (-2.02, -0.10) 
 Any DR (n=126) -0.77 (-1.65, 0.12) -0.82 (-2.50, 0.86) 
 Difference in average outer retinal thickness 
 Age-gender adjusted Model 2
a
 
Controls with no DM (Reference) (Reference) 
Cases with DM (n=224) 2.55 (0.97, 4.12) 2.03 (-0.08, 4.13) 
Cases stratified by DR status   
 No DR (n=100) 1.95 (-0.16, 4.06) 1.68 (-0.64, 4.00) 
 Any DR (n=124) 3.03 (1.24, 4.83) 2.55 (0.08, 5.02) 
DM = diabetes mellitus; DR = diabetic retinopathy; GC-IPL = ganglion cell-inner plexiform layer; 
RNFL = retinal nerve fibre layer.
  
a












Table 4.3. Mean difference in µm (95% confidence interval) in intraretinal layer thickness of 
retinal ganglion cells between DR severity levels among subjects with diabetes 
 Difference in average GC-IPL thickness 





No DR (n=101) (Reference) (Reference) (Reference) 
Any DR (n=126) -0.56 (-2.42, 1.30) -1.60 (-3.35, 0.16) -1.47 (-3.28, 0.34) 
Stratified by DR severity    
 Mild DR (n=25) -0.16 (-2.93, 2.62) -0.64 (-3.34, 2.06) -0.78 (-3.52, 1.95) 
 Moderate or severe  DR 
(n=101) 
-0.65 (-2.65, 1.35) -2.02 (-3.94, -0.11) -2.07 (-4.07, -0.08) 
 Difference in average RNFL thickness 





No DR (n=101) (Reference) (Reference) (Reference) 
Any DR (n=126) -0.01 (-1.06, 1.04) 0.14 (-0.94, 1.21) -0.03 (-1.18, 1.13) 
Stratified by DR severity    
 Mild DR (n=25) 0.54 (-1.37, 2.45) 0.53 (-1.29, 2.34) 0.35 (-1.46, 2.16) 
 Moderate or severe  DR 
(n=101) 
-0.15 (-1.27, 0.97) -0.04 (-1.20, 1.12) -0.35 (-1.62, 0.92) 
DM = diabetes mellitus; DR = diabetic retinopathy; GC-IPL = ganglion cell-inner plexiform layer; 
RNFL = retinal nerve fibre layer.
  
a
Adjusted for age, gender, axial length, OCT signal strength, HbA1c and mean arterial blood 
pressure. 
b
Adjusted for covariates as in Model 2 and diabetes duration. 
c
Reduced sample size for no DR (n=95) and moderate or severe DR (n=99) due to missing values 
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Figure 4.2. Cirrus HD-OCT Ganglion Cell Analysis protocol. (A) Right eye foveal 
centered elliptical annulus showing vertical and horizontal dimensions. The annulus is 
divided into six equally sized sectors. (B) Segmented retinal nerve fibre layer (the 
thickness was calculated as the distance between red and blue lines), ganglion cell-inner 
plexiform layer (the thickness was calculated as the distance between blue and yellow 
lines), and outer retina (the thickness was calculated as the distance between dotted lines) 











































5.1. Summary of Findings 
 
The present study found that the evaluation of RGCs using spectral-domain OCT 
should be represented by separate measurements of GC-IPL and RNFL parameters. 
This is as opposed to the measurement of GCC parameter, i.e. sum of GC-IPL and 
RNFL thicknesses, which gives asymmetric representation between axons, and 
ganglion cell bodies and dendrites. By measuring GC-IPL and RNFL thicknesses 
separately, the present study showed that in subjects with DM, RGC neurons are 
vulnerable to damage prior to the onset of apparent microvascular DR lesions 
compared with healthy controls, as reflected by GC-IPL thinning, and such RGC 
damage is likely to progress in subsequent severe forms of DR development. 
 
5.2. Clinical Significance 
 
With the growing application of OCT as an ancillary procedure to detect and 
monitor various macular diseases (e.g. diabetic macular edema, and neurosensory 
retinal detachment),
109,157
 the present study showed that OCT can quantity RGC loss, 
as a proxy for neuronal damage, associated with  hypoxic-ischemic changes in DR. In 
this regard, clinical assessment of diabetes-induced retinal damage should parallel the 
notion that DR is a neurovascular disease. Findings from the present study 
imperatively raise the potential for the inclusion of OCT in clinical assessment as a 
simple, accessible and more sensitive means of detecting diabetes-induced retinal 
damage compared to clinical routine examination of the retinal microvasculature. The 
presence of microvascular DR damage can be detected with routine fundus 
examination techniques, such as slit-lamp indirect biomicroscopy. However, the 
absence of apparent microvascular lesions may not necessarily indicate the absence 
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of diabetes-induced retinal damage. In this regard, further investigation into damages 
of the layered neurosensory retina in DR damage should be administered using OCT. 
 
Although the present study found that RGC loss is associated with severe forms 
of DR, it remains inconclusive whether RGC neuronal damage is caused by the direct 
effect of hypoxia-ischemia or is merely a coexistence with microvascular damage. 
The present study finding of RGC loss even in the absence of apparent microvascular 
DR lesions, suggests that clinically apparent damages to the neuronal layers of the 
retina and retinal microvasculature occur at different rate, with the former as an 
earlier change. Further studies are recommended to evaluate whether retinae with 
neuronal damage are predispose to progression of microvascular DR, as an 
integrative approach of DR monitoring.  
 
5.3. Strengths and Limitations 
 
Strengths of the current study include the measurement of retinal parameters at 
the macular region using a reliable and reproducible spectral-domain OCT 
algorithm.
120
 Furthermore, with the current algorithm we were able to measure 
specific layers of the retina (e.g. the GC-IPL). Standardized protocols were strictly 
followed during retinal photography and in the grading of DR severity to ensure 
reliable characterization of DR states. Lastly, as opposed to previous studies, the 
effect of several potential confounders was controlled to manifest independent 
associations.  
 
Several limitations of the current study need to be discussed. Firstly, we were not 
able to examine the link with severe DR specifically, as we only had small number of 
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cases with severe DR. Secondly, the cross-sectional design did not give us an 
opportunity to examine the temporal link between neuronal damage and the 
appearance of microvascular lesions. Lastly, the RNFL thickness was measured at the 
macular region, where the layer is anatomically thinner than the region around the 
optic nerve head, where it is usually measured. This thinner RNFL region may have 
introduced more measurement error.  
 
5.4. Future Directions 
 
The present study finding of diabetes-induced RGC neuronal damage in the 
absence of clinically apparent DR has raised the question of the temporal link 
between neuronal damage and apparent microvascular lesions. 
 
Further studies are required to confirm whether retinal neurodegeneration is an 
early feature of DR. The key question is to investigate whether neuronal damage is 
manifested prior to the onset of apparent microvascular DR lesions. This would 
require a prospective longitudinal study to examine the association of RGC loss with 
incident microvascular DR. The temporal link, once established would be appealing 
in several ways. Firstly, loss of RGCs can act as marker to predict the risk of DR 
and/or DR progression before visual loss occurs. Furthermore, the knowledge on 
retinal neuronal damage in DM can be integrated into the existing clinical grading of 
microvascular DR to revise the classification and therapeutic guidelines on DR. 
Finally, if DR is diagnosed clinically on the basis of neuronal damage prior to the 
onset of apparent microvascular lesions, this interval could provide the most 






The present study demonstrated that RGC neuronal damage, as reflected by GC-
IPL thinning, is present in subjects with DM and no clinically apparent microvascular 
DR lesions, and such neuronal damage is likely to progress in subsequent moderate 
or severe DR development. These data provide evidence of early neuronal damage in 
DM, and an interaction between DR hypoxia-ischemia and RGC damage, which are 
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